BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Market Outperform” Rating from JMP Securities
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a research report issued on Friday,Benzinga reports. They presently have a $18.00 price target on the biotechnology company’s stock. JMP Securities’ price objective would indicate a potential upside of 127.13% from the company’s current […]
More Stories
Trade Court Upholds Trump’s Shutdown of $800 De Minimis Duty Exemption
By Matthew Vadum The U.S. Court of International Trade on Aug. 13 upheld the Trump administration’s authority to end the...
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...
State Department Launches Birth Tourism Prevention Task Force
By Troy Myers The Department of State on Wednesday announced the existence of a task force that has already revoked...
Todd Blanche Sworn In as Attorney General
By Kimberly Hayek Todd Blanche, President Donald Trump’s former personal lawyer, was sworn in Monday as U.S. attorney general and...
16,000 Arrests Made as Part of Operation to Make Washington Safe
By Naveen Athrappully More than 16,000 individuals have been arrested in Washington since the launch of the Make D.C. Safe...